Insulin The Focus At ADA 2012, But Don’t Forget GLP-1s And SGLT-2s
This article was originally published in The Pink Sheet Daily
Executive Summary
In anticipation of the American Diabetes Conference of 2012, analysts take a look at several categories of drugs that will be playing a major role in the future of diabetes care.
You may also be interested in...
Ember Therapeutics Angles For Lead In ‘Brown Fat’ Therapeutics
Ember’s co-founder Bruce Spiegelman explained in the Banting Lecture at the American Diabetes Association earlier in June how his lab at Harvard discovered the hormone irisin, which appears to be a key regulator of fat metabolism and may be responsible for beneficial functions of ‘brown’ fat.
“Brown Fat” Attracts Start-Up Interest, Highlighted At ADA 2012
Bruce Spiegelman, co-founder of the start-up Ember Therapeutics and winner of ADA’s prestigious Banting Award, described how his lab at Harvard discovered the hormone irisin, which appears to be a key regulator of fat metabolism and may be responsible for beneficial functions of “brown” fat.
New Long-Acting Insulin Offerings Could Derail Lantus Franchise
Companies presented data at ADA that could give patients options other than Lantus, but Sanofi is fighting back with a strategy to retain them.